Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 267-225-7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

SpencerF Aug. 7 at 2:02 PM

$BCRX $CNTX I assume we’re still fighting issues with the whole sector that began in 2021. Think there will ever be wave of run ups for small caps/ bio again? Why are there never any runs to burn the shorts etc for 4 whole years now? Makes no sense that the people controlling the market would want to allow something to be a 100% safe investment, puts and shorting. Why not every once in a while let something run and destroy people’s puts or ruin short positions? Or can it even be 5, 6 year plus waves?

2 · Reply

JarvisFlow Aug. 7 at 12:00 PM

D. Boral Capital has adjusted their stance on Context Therapeutics ( $CNTX ), setting the rating to Buy with a target price of 9.

0 · Reply

JarvisFlow Aug. 7 at 11:00 AM

HC Wainwright & Co. has updated their rating for Context Therapeutics ( $CNTX ) to Buy with a price target of 4.

0 · Reply

VA_24 Aug. 6 at 10:12 PM

$CNTX https://x.com/context_tx/status/1953189198501941301?s=46&t=RHvaW8uvjAmnLXLy0NT30w

0 · Reply

F_The_short Aug. 5 at 11:18 PM

$CNTX 🚀🚀🚀🚀🚀🚀

0 · Reply

SpencerF Aug. 5 at 1:45 PM

$CNTX how much longer till the RS / End of company? Still have a few months for a miracle to happen?

1 · Reply

F_The_short Aug. 4 at 8:56 PM

$CNTX This is for the fuuuucking shorts😡😡😡😡

0 · Reply

SpencerF Aug. 4 at 8:12 PM

$CNTX off to zero we go weeee, guess they haven’t developed anything afterall

0 · Reply

VA_24 Aug. 4 at 7:59 PM

$CNTX

0 · Reply

SpencerF Aug. 1 at 5:04 PM

$CNTX come on Mr ceo, let’s hear your end of company closing statement.

1 · Reply

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Jun 10, 2025, 7:10 AM EDT - 2 months ago

Context Therapeutics: Undervalued Cancer Fighter

Jun 2, 2025, 7:30 AM EDT - 2 months ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

May 29, 2025, 7:30 AM EDT - 2 months ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 12, 2025, 4:38 PM EDT - 3 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 7, 2025, 4:09 PM EDT - 3 months ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 5, 2025, 4:05 PM EDT - 3 months ago

Context Therapeutics Announces Chief Medical Officer Transition

Apr 30, 2025, 7:30 AM EDT - 3 months ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 9, 2025, 7:30 AM EDT - 4 months ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Apr 1, 2025, 7:30 AM EDT - 4 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences

Mar 26, 2025, 4:02 PM EDT - 4 months ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 5 months ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Jan 14, 2025, 4:58 PM EST - 7 months ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 7 months ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 6, 2024, 4:06 PM EST - 9 months ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 23, 2024, 7:30 AM EDT - 10 months ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 7:30 AM EDT - 10 months ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 10, 2024, 2:06 PM EDT - 1 year ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 8, 2024, 4:06 PM EDT - 1 year ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 2, 2024, 7:31 AM EDT - 1 year ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 7:43 AM EDT - 1 year ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Apr 18, 2023, 10:15 AM EDT - 2 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 3, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 22, 2023, 5:08 PM EDT - 2 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 15, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 4, 2023, 7:30 AM EST - 2 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Dec 8, 2022, 7:30 AM EST - 2 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Nov 29, 2022, 7:30 AM EST - 2 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 21, 2022, 9:11 AM EST - 2 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 9, 2022, 4:14 PM EST - 2 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

Sep 27, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

Sep 6, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022, 4:01 PM EDT - 3 years ago

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

Aug 2, 2022, 9:59 AM EDT - 3 years ago

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

May 11, 2022, 4:01 PM EDT - 3 years ago

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

Apr 11, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

SpencerF Aug. 7 at 2:02 PM

2 · Reply

JarvisFlow Aug. 7 at 12:00 PM

D. Boral Capital has adjusted their stance on Context Therapeutics ( $CNTX ), setting the rating to Buy with a target price of 9.

0 · Reply

JarvisFlow Aug. 7 at 11:00 AM

HC Wainwright & Co. has updated their rating for Context Therapeutics ( $CNTX ) to Buy with a price target of 4.

0 · Reply

VA_24 Aug. 6 at 10:12 PM

$CNTX https://x.com/context_tx/status/1953189198501941301?s=46&t=RHvaW8uvjAmnLXLy0NT30w

0 · Reply

F_The_short Aug. 5 at 11:18 PM

$CNTX 🚀🚀🚀🚀🚀🚀

0 · Reply

SpencerF Aug. 5 at 1:45 PM

$CNTX how much longer till the RS / End of company? Still have a few months for a miracle to happen?

1 · Reply

F_The_short Aug. 4 at 8:56 PM

$CNTX This is for the fuuuucking shorts😡😡😡😡

0 · Reply

SpencerF Aug. 4 at 8:12 PM

$CNTX off to zero we go weeee, guess they haven’t developed anything afterall

0 · Reply

VA_24 Aug. 4 at 7:59 PM

$CNTX

0 · Reply

SpencerF Aug. 1 at 5:04 PM

$CNTX come on Mr ceo, let’s hear your end of company closing statement.

1 · Reply

rp6577 Aug. 1 at 1:44 PM

$CNTX Show me 0.60 again and I’ll be back in

0 · Reply

SpencerF Aug. 1 at 12:23 PM

$CNTX naked short to 40 cents today? Or are they just using regular shorting for now?

1 · Reply

F_The_short Jul. 31 at 11:57 PM

$CNTX Shorts are nothing but a fucking scam 😡😡😡😡😡😡😡😡😡😡

0 · Reply

F_The_short Jul. 31 at 11:53 PM

$CNTX So criminals manipulating the stock down 😡😡😡😡

0 · Reply

VA_24 Jul. 31 at 7:07 PM

$CNTX these fucks of CEOs of small caps don’t give a flying fuck about retail. Zero communication SMDH Say something bitch

1 · Reply

SpencerF Jul. 31 at 6:41 PM

$CNTX bout time to let the shorts finish her off to zero? Or is there still a little time left to work towards $1?

0 · Reply

F_The_short Jul. 31 at 6:39 PM

$CNTX 😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡😡

0 · Reply

HoHoHoHum Jul. 31 at 5:14 PM

$CNTX one of the most frustrating plays!

0 · Reply

F_The_short Jul. 31 at 12:04 PM

$CNTX 😂😂😂😂😂😂😂🚀🚀🚀🚀🚀🚀🚀🚀🚀Fuck the shorts 🚀🚀🚀🚀

0 · Reply

F_The_short Jul. 25 at 12:55 AM

$CNTX 🚀🚀🚀🚀🚀🚀🚀😂😂😂😂😂🤪🤪😆😆😆

0 · Reply

leonverona Jul. 24 at 10:39 AM

$CNTX premarket up . Open market down !

0 · Reply

F_The_short Jul. 23 at 12:32 PM

$CNTX 🚀🚀🚀🚀🚀🚀🚀😂😂😂😂😂😂

0 · Reply

Market Cap	62.70M
Revenue (ttm)	0.00
Net Income (ttm)	-26.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	116,100
Avg Vol	270,818
Day's Range	N/A - N/A
Shares Out	89.70M
Stochastic %K	22%
Beta	1.89
Analysts	Strong Sell
Price Target	$5.40